Pharvaris B.V. (id:8143 PHVS)
18.93 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/24/2024 11:17:01 AM)
Exchange open, closes in 4 hours 42 minutes
-1.35 USD (-1.35%)
1.18 USD (1.18%)
-7.88 USD (-7.88%)
3.33 USD (3.33%)
-29.37 USD (-29.37%)
-24.28 USD (-24.28%)
About Pharvaris B.V.
Market Capitalization 1.06B
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
| Headquarters (address) |
Emmy Noetherweg 2 Leiden 2333 BK Netherlands |
| Phone | 31 71 203 6410 |
| Website | https://pharvaris.com |
| Employees | 83 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | PHVS |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 15.37 - 33.00 |
| Market Capitalization | 1.06B |
| P/E trailing | -7.44 |
| P/E forward | -6.42 |
| Price/Book | 2.66 |
| Beta | -3.14 |
| EPS | -2.73 |
| EPS Netherlands (ID:23, base:88) | 1.55 |